美股详情

本页面由Tiger Trade Technology Pte. Ltd.提供服务

Rxi Pharmaceuticals Corp

0.3302

0.0000

成交量：- -

成交额：- -

市值：144.51万

市盈率：-0.11

高：0.3302

开：0.3302

低：0.3302

收：0.3302

52周最高：7.70

52周最低：0.3100

股本：437.63万

流通股本：230.08万

量比：- -

换手率：- -

股息：- -

股息率：- -

每股收益(TTM):-3.0991

每股收益(LYR):-5.5152

净资产收益率：--

总资产收益率：--

市净率：0.44

市盈率(LYR):-0.06

数据加载中...

总览公司新闻资讯公告

公司资料

公司名字：

Rxi Pharmaceuticals Corp

交易所：

NASDAQ

成立时间：

- -

员工人数：

- -

公司地址：

- -

官网：

http://www.rxipharma.com

邮编：

- -

电话：

- -

传真：

- -

简介：

Rxi Pharmaceuticals Corporation是一家生物技术公司，基于公司专有的新一代核糖核酸干扰(RNAi)平台专注于发现、开发和商业化创新疗法。由于这些疗法得“沉默”能力,或者说是其下调能力,病态情况下的特定基因可以被分析的更为清楚，所以基于RNAi平台的疗法更有说服力的。2011年9月8日之前,该公司的业务由其非操作部门Galena Biopharma公司（该公司的前母公司）来完成。公司成立于特拉华州，作为Galena 的全资子公司。2011年9月8日开始，其计划并准备与Galena脱离。2012年4月27日这一计划得以完成。至此之后,公司作为一个独立的上市公司运营。

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/stock/RXII/company"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"RXII","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"RXII\",,,,,undefined,":{"symbol":"RXII","market":"US","secType":"STK","nameCN":"Rxi Pharmaceuticals Corp","latestPrice":0.3302,"timestamp":1542401999999,"preClose":0.3302,"halted":8,"volume":0,"delay":0,"changeRate":0,"floatShares":2300823,"shares":4376322,"eps":-3.099079,"marketStatus":"交易中","change":0,"latestTime":"02-26 13:41:08 EST","open":0.3302,"high":0.3302,"low":0.3302,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-3.099079,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1772139600000},"marketStatusCode":2,"symbolChange":{"newSymbol":"PHIO","executeDate":"2018-11-19"},"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":0.3302,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"RXII\",,,,,undefined,":{"symbol":"RXII","floatShares":2300823,"roa":"--","roe":"--","lyrEps":-5.515215,"shares":4376322,"dividePrice":0,"high":0.3302,"amplitude":0,"preClose":0.3302,"low":0.3302,"week52Low":0.31,"pbRate":"0.44","week52High":7.7,"institutionHeld":0,"latestPrice":0.3302,"eps":-3.099079,"divideRate":0,"volume":0,"delay":0,"ttmEps":-3.099079,"open":0.3302},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/RXII\",params:#limit:5,,,undefined,":[{"date":"2018-11-19","symbol":"RXII","newSymbol":"PHIO","type":"symbolChange","dateTimestamp":1542603600000},{"market":"US","date":"2018-11-14","symbol":"RXII","fiscalQuarterEnding":"2018/09","expectedEps":-0.45,"name":null,"time":"盘后","type":"earning","dateTimestamp":1542171600000,"reportTimeType":"post","actualEps":-0.34},{"market":"US","date":"2018-08-14","symbol":"RXII","fiscalQuarterEnding":"2018/06","expectedEps":-0.59,"name":null,"time":"盘后","type":"earning","dateTimestamp":1534219200000,"reportTimeType":"post","actualEps":-0.46},{"market":"US","date":"2018-05-10","symbol":"RXII","fiscalQuarterEnding":"2018/03","expectedEps":null,"name":null,"time":"盘后","type":"earning","dateTimestamp":1525924800000,"reportTimeType":"post","actualEps":-0.9},{"market":"US","date":"2018-03-26","symbol":"RXII","fiscalQuarterEnding":"2017/12","expectedEps":-0.96,"name":null,"time":"","type":"earning","dateTimestamp":1522036800000,"reportTimeType":"","actualEps":-0.84}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"RXII\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"RXII\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"stock.company.info\",,undefined,":{"stockCompanyProfile":{},"stockCompanyDetail":{"websiteUrl":"http://www.rxipharma.com","stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":0},{"period":"3month","weight":0},{"period":"6month","weight":0},{"period":"1year","weight":0},{"period":"ytd","weight":0}],"compareEarnings":[{"period":"1week","weight":0.01},{"period":"1month","weight":0.0006},{"period":"3month","weight":0.0198},{"period":"6month","weight":0.0746},{"period":"1year","weight":0.1664},{"period":"ytd","weight":0.0165}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Rxi Pharmaceuticals Corporation是一家生物技术公司，基于公司专有的新一代核糖核酸干扰(RNAi)平台专注于发现、开发和商业化创新疗法。由于这些疗法得“沉默”能力,或者说是其下调能力,病态情况下的特定基因可以被分析的更为清楚，所以基于RNAi平台的疗法更有说服力的。2011年9月8日之前,该公司的业务由其非操作部门Galena Biopharma公司（该公司的前母公司）来完成。公司成立于特拉华州，作为Galena 的全资子公司。2011年9月8日开始，其计划并准备与Galena脱离。2012年4月27日这一计划得以完成。至此之后,公司作为一个独立的上市公司运营。","exchange":"NASDAQ","name":"Rxi Pharmaceuticals Corp","nameEN":"RXi Pharmaceuticals"}},"@#url:\"https://hq.skytigris.cn/fundamental/company/manager/list\",params:#symbol:\"RXII\",market:\"US\",,,undefined,":null}}